No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGDm | 144 | 338 | 233 | 101 | 115 | 144 | N/A | N/A |
| Operating profit | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SGDm | 13 | 119 | 37 | -21 | -6 | -4 | N/A | N/A |
| EPS reported | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
UG Healthcare Corporation Limited, an investment holding company established in Singapore in 1989, primarily engages in the manufacturing and worldwide distribution of disposable gloves. Its business is structured across three main segments: Latex Examination Gloves, Nitrile Examination Gloves, and a category for Other Ancillary Products. The company's offerings include both latex examination gloves, available in single and double chlorinated polymer-coated varieties, as well as nitrile examination gloves. Additionally, it supplies a range of supplementary items like surgical gloves, vinyl and cleanroom disposable gloves, face masks, various other medical disposables, and protective shoe covers. The firm also extends its expertise through business and management consultancy services. Its products serve diverse sectors such as healthcare, food and beverage, industrial and high-technology manufacturing, automotive, research and development, and the beauty industry. Operating under its "Unigloves" brand name, the corporation reaches customers across Malaysia, Europe, North America, South America, Africa, and the broader Asian market.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
UG Healthcare Corporation Limited (8K7.SI)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
UG Healthcare Corporation Limited, an investment holding company established in Singapore in 1989, primarily engages in the manufacturing and worldwide distribution of disposable gloves. Its business is structured across three main segments: Latex Examination Gloves, Nitrile Examination Gloves, and a category for Other Ancillary Products. The company's offerings include both latex examination gloves, available in single and double chlorinated polymer-coated varieties, as well as nitrile examination gloves. Additionally, it supplies a range of supplementary items like surgical gloves, vinyl and cleanroom disposable gloves, face masks, various other medical disposables, and protective shoe covers. The firm also extends its expertise through business and management consultancy services. Its products serve diverse sectors such as healthcare, food and beverage, industrial and high-technology manufacturing, automotive, research and development, and the beauty industry. Operating under its "Unigloves" brand name, the corporation reaches customers across Malaysia, Europe, North America, South America, Africa, and the broader Asian market.